WHO approves LC16m8 Vaccine for Mpox Emergency Use to Tackle Global Outbreak

World Health Organization (WHO) has approved the emergency use listing (EUL) of the "LC16m8" vaccine to address the ongoing mpox outbreak, WHO (19/11).

Dr Yukiko Nakatani, WHO Assistant Director-General for Access to Medicines and Health Products, said "WHO emergency use listing of the LC16m8 vaccine against mpox marks a significant step in our response to the current emergency, providing a new option to protect all populations, including children".

She emphasized that WHO's action aims to mitigate the catastrophic outbreak of monkeypox---the virus responsible for mpox---which has affected people indiscriminately. The vaccine will be especially beneficial for communities in affected regions, particularly in Africa, where the disease is endemic.

"Vaccines are one of the important tools to help contain the outbreak as part of a comprehensive response strategy that also includes improved testing and diagnosis, treatment and care, infection prevention and control, and engagement and education within affected communities," she added.

Dr. Nakatani highlighted the urgent need for a global response, given the thousands of deaths caused by mpox. This response should prioritize diagnosing and preventing new infections, establishing adequate vaccine supplies, and providing treatment for infected individuals. She also stressed the importance of public communication to educate communities about how the vaccine can save lives. The LC16m8 Mpox vaccine stands as a vital tool in the emergency response to the outbreak.

Sources:

https://www.who.int/news/item/19-11-2024-who-adds-lc16m8-mpox-vaccine-to-emergency-use-listing

https://www.who.int/indonesia/id/emergencies/mpox-outbreak